NetworkNewsBreaks – AcelRx Pharmaceuticals, Inc. (ACRX) to Present ARX-04 SAP303 Study Results at Annual ASRA Pain Medicine Meeting
AcelRx Pharmaceuticals (NASDAQ: ACRX), focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, this morning announced its upcoming presentation of the complete results from the phase 3 SAP303 study of ARX-04. The presentation will take place at the ongoing 15th Annual Pain Medicine Meeting of the American Society of Regional Anesthesia and Pain Medicine (ASRA). To view the full press release, visit: http://nnw.fm/3cX1B About AcelRx Pharmaceuticals, Inc. AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company's…







